Margetuximab in HER2-positive metastatic breast cancer

This review article highlights the development of the novel, Fc-engineered, anti-HER2 monoclonal antibody margetuximab-cmkb for the systemic treatment of patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 treatments, at least one of which for metastatic disease.